Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > The critters are restless and angry

<< Previous

Bullboard Posts

Next >>

Comment by bud13on Feb 17, 2021 10:20pm

115 Views

Post# 32592579

RE:RE:RE:The critters are restless and angry

well. I grew up on moonshine. So I'll have to say from what happened with the GVHD program Robert will have to prove himself after that $hit show. I'm sitting here with 1.8m shares and Robert give me nothing to show for it. So at this point he'll have to prove himself at least to me. Bring it in Robert.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing